124 related articles for article (PubMed ID: 26988821)
1. [RNPC1 induces sensitivity of HER-2-positive breast cancer BT474 cells to trastuzumab through upregulation of HER2].
Li CL; Zhou XJ; Lou PP; Xia TS; Shi L; Wang Y; Ding Q
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):172-8. PubMed ID: 26988821
[TBL] [Abstract][Full Text] [Related]
2. [Regulatory effect and mechanism of RNA binding motif protein 38 on the expression of progesterone receptor in human breast cancer ZR-75-1 cells].
Lou PP; Li CL; Xia TS; Shi L; Wu J; Zhou XJ; Wang Y; Ding Q
Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):425-9. PubMed ID: 27346399
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
Milella M; Trisciuoglio D; Bruno T; Ciuffreda L; Mottolese M; Cianciulli A; Cognetti F; Zangemeister-Wittke U; Del Bufalo D; Zupi G
Clin Cancer Res; 2004 Nov; 10(22):7747-56. PubMed ID: 15570009
[TBL] [Abstract][Full Text] [Related]
4. RNPC1 enhances progesterone receptor functions by regulating its mRNA stability in breast cancer.
Lou P; Li C; Shi L; Xia TS; Zhou W; Wu J; Zhou X; Li X; Wang Y; Wei JF; Ding Q
Oncotarget; 2017 Mar; 8(10):16387-16400. PubMed ID: 27634883
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
6. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
[TBL] [Abstract][Full Text] [Related]
7. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
[TBL] [Abstract][Full Text] [Related]
8. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
9. FOXO1A is a target for HER2-overexpressing breast tumors.
Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
[TBL] [Abstract][Full Text] [Related]
11. Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer.
Dong H; Wang W; Chen R; Zhang Y; Zou K; Ye M; He X; Zhang F; Han J
Int J Oncol; 2018 Sep; 53(3):1013-1026. PubMed ID: 30015837
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines.
Gu L; Lau SK; Loera S; Somlo G; Kane SE
Clin Cancer Res; 2009 Dec; 15(23):7196-206. PubMed ID: 19920112
[TBL] [Abstract][Full Text] [Related]
13. Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
Wells V; Mallucci L
Breast Cancer Res; 2009; 11(1):R2. PubMed ID: 19133120
[TBL] [Abstract][Full Text] [Related]
14. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
Chakrabarty A; Sánchez V; Kuba MG; Rinehart C; Arteaga CL
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2718-23. PubMed ID: 21368164
[TBL] [Abstract][Full Text] [Related]
15. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer.
Dong H; Hu J; Zou K; Ye M; Chen Y; Wu C; Chen X; Han M
Mol Cancer; 2019 Jan; 18(1):3. PubMed ID: 30621694
[TBL] [Abstract][Full Text] [Related]
16. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
[TBL] [Abstract][Full Text] [Related]
17. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
[TBL] [Abstract][Full Text] [Related]
18. RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer.
Xue JQ; Xia TS; Liang XQ; Zhou W; Cheng L; Shi L; Wang Y; Ding Q
BMC Cancer; 2014 May; 14():322. PubMed ID: 24884756
[TBL] [Abstract][Full Text] [Related]
19. Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.
Zhao Z; Li R; Sha S; Wang Q; Mao W; Liu T
Cancer Biol Ther; 2014 Oct; 15(10):1404-12. PubMed ID: 25046105
[TBL] [Abstract][Full Text] [Related]
20. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells.
Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1315-23. PubMed ID: 21461888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
